Feed-based metaphylaxis programs did not
affect health or performance of high-risk
calves mass medicated with Draxxin on arrival by Epp, M.P. et al.
26
Management
Feed-Based Metaphylaxis Programs Did Not 
Affect Health or Performance of High-Risk 
Calves Mass Medicated with Draxxin on Arrival 
D.A Blasi, M P. Epp, and R. Derstein 
Introduction
Bovine	respiratory	disease	continues	to	be	the	most	costly	disease	affecting	productivity	
and	profitability	in	the	stocker	segment.	Despite	their	high	cost,	longer-acting,	inject-
able	therapeutic	antimicrobials	such	as	Draxxin	(Tulathromycin;	Pfizer	Animal	Health,	
New	York,	NY)	can	extend	the	window	of	treatment	duration,	thereby	reducing	the	
incidence	and	severity	of	bovine	respiratory	disease.	Use	of	feed-based	metaphylaxis	
programs,	such	as	therapeutic	administration	of	multiple	5-day	pulses	of	Aureomycin	
(Alpharma,	Inc.,	Bridgewater,	NJ),	in	conjunction	with	an	injectable	metaphylaxis	
program	may	be	a	cost-effective	way	to	improve	bovine	respiratory	disease	therapy	with-
out	having	to	physically	handle	and	stress	cattle.
Experimental Procedures
One	55-day	receiving	study	was	conducted	at	the	Kansas	State	University	Beef	Stocker	
Unit	during	May	2008	to	determine	the	response	of	high-risk	stocker	calves	to	concur-
rent	metaphylaxis	with	Draxxin	and	Aureomycin.	All	cattle	were	sourced	from	an	order	
buyer	in	Tennessee,	and	cattle	were	received	over	3	consecutive	days.	Upon	arrival,	
all	calves	were	weighed,	tagged,	mass	medicated	with	Draxxin	(1.1	mL/100	lb),	and	
palpated	for	gender	(bull	or	steer).	Calves	were	then	given	free-choice	access	to	long-
stem	prairie	hay	and	water.	The	following	day,	calves	were	vaccinated	against	clostridial	
and	respiratory	diseases	and	dewormed,	and	bulls	were	surgically	castrated.	Each	load	
(three	total)	was	then	blocked	by	arrival	date	and	randomly	assigned	to	one	of	three	
treatments	for	a	total	of	24	pens.	Castrated	bulls	were	distributed	equally	among	the	
eight	pens	within	each	alley.	Cattle	were	weighed	and	revaccinated	12	days	after	initial	
processing	and	weighed	again	following	the	55-day	feeding	period.	Calves	were	stepped	
up	using	three	sequential	growing	diets	ranging	from	29%	to	36.5%	concentrate.	Diets	
were	fed	with	addition	of	one	of	the	following	three	treatments:	(1)	no	top-dress	pellets	
(control);	(2)	top-dressed	with	Aureomycin-containing	pellets	(10	mg	chlortetracycline	
per	pound	of	body	weight)	on	days	8	to	12,	14	to	18,	20	to	24,	and	26	to	30	post-arrival;	
or	(3)	top-dressed	with	Aureomycin	pellets	on	days	0	to	4,	6	to	10,	12	to	16,	18	to	22,	
and	24	to	28	followed	by	25	days	of	administration	of	AS-700	(Alpharma,	Inc.),	which	
provided	350	mg/head	per	day	of	both	chlortetracycline	and	sulfamethazine.	All	treat-
ments	received	Bovatec	(Alpharma,	Inc.)	at	250	to	300	mg/head	daily	in	the	complete	
feed	for	the	first	28	days	on	study.	The	control	and	Aureomycin-only	treatments	
received	Bovatec	from	day	29	until	conclusion	of	the	study.
Cattle	were	observed	daily	for	signs	of	illness	and	injury	by	personnel	blinded	to	treat-
ments.	Calves	were	treated	for	respiratory	disease	with	Draxxin	only	after	a	moratorium	
of	5	days	post-metaphylaxis.	Calves	determined	to	need	treatment	were	given	Baytril	
(Bayer	Animal	Health,	Shawnee	Mission,	KS)	at	5	mL/100	lb	body	weight	as	a	first	
treatment;	Nuflor	(Intervet/Schering-Plough	Animal	Health,	Millsboro,	DE)	at		
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6	mL/100	lb	body	weight	as	a	second	treatment,	if	needed;	and	Bio-Mycin	200	(Boeh-
ringer	Ingelheim,	Ridgefield,	CT)	at	4.5	mL/100	lb	body	weight	as	a	third	treatment,		
if	needed.
Bunks	were	checked	twice	daily,	and	feed	was	delivered	in	amounts	sufficient	to	result	
in	slick	bunks	both	morning	and	afternoon.	Calves	were	fed	their	respective	diets	at	
approximately	7:00	a.m.	and	3:00	p.m.	daily	for	55	days.
Daily	dry	matter	intake,	gains,	and	feed	efficiencies	were	determined	for	each	pen	
of	calves.	Health	records	were	used	to	determine	the	number	of	animals	treated	and	
percentage	of	death	loss.	
Performance	and	health	data	were	analyzed	by	using	the	random	effects	MIXED	
model	procedure	SAS	(SAS	Institute,	Inc.,	Cary,	NC).	Treatments	were	arranged	in	a	
randomized	incomplete	block	design;	pen	served	as	the	experimental	unit	for	growth	
and	health	characteristic	analysis.	In	the	model,	fixed	effects	were	treatment,	lot,	and	
gender,	and	random	effects	were	lot	×	treatment,	pen,	and	animal	ID.	Percentages	of	
morbidity	and	mortality	were	evaluated	by	the	Chi-Square	test,	and	differences	were	
declared	significant	at	P<0.05.
Results and Discussion
There	were	no	significant	differences	among	treatments	in	the	percentage	of	steers	
treated	once,	twice,	or	one	or	more	times	for	bovine	respiratory	disease	(P>0.30;		
Table	1).	There	were	no	significant	differences	in	daily	gain	(P=0.66),	daily	dry	matter	
intake	(P=0.68),	or	feed	efficiency	(P=0.50)	among	the	three	treatments.
Implications
This	experiment	showed	no	benefit	of	feeding	Aureomycin	for	four	5-day	periods	after	
receiving	when	calves	were	mass	medicated	with	Draxxin	upon	arrival.	These	results	
may	be	beneficial	to	producers	who	are	evaluating	treatment	protocols	for	newly	
received	high-risk	stocker	calves.
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Table 1. Treatment incidence for bovine respiratory disease (BRD), percentage of death loss, and growth perfor-
mance of newly arrived stocker calves receiving injectable and feed-based metaphylaxis programs during a 55-day 
receiving study
Treatment1
Item Draxxin
Draxxin	plus	
Aureomycin
Draxxin	plus	
Aureomycin	
plus	AS-700 SEM P-value
No.	of	pens 8 8 8
No.	of	steers 32 32 31
No.	of	castrated	bulls 72 73 73
Initial	weight,	lb 453 449 452 4.0 0.79
Weight	at	revaccination,	lb 507 507 505 5.0 0.97
Final	weight,	lb 616 613 622 6.0 0.58
Treatments	for	BRD,	%	of	calves
Treated	only	once 15.2 22.6 18.8 3.3 0.30
Treated	two	times	or	more 24.6 21.2 16.6 4.7 0.49
Total	BRD	treatment,	one	or	more	times 39.8 43.8 35.4 4.8 0.48
Death	loss,	% 0 0.84 2.18 1.2 0.39
Daily	dry	matter	intake,	lb 14.54 14.31 14.68 0.31 0.68
Average	daily	gain,	lb 3.02 3.04 3.15 0.10 0.66
Feed:Gain 4.92 4.81 4.78 0.08 0.50
1	Draxxin,	calves	administered	Draxxin	upon	arrival;	Draxxin	plus	Aureomycin,	calves	administered	Draxxin	upon	arrival	in	addition	to	pulse	dosing	
of	Aureomycin	on	days	8	to	12,	14	to	18,	20	to	24,	and	26	to	30	post-arrival;	Draxxin	plus	Aureomycin	plus	AS-700,	calves	administered	Draxxin	
upon	arrival	in	addition	to	pulse	dosing	of	Aureomycin	on	days	0	to	4,	6	to	10,	12	to	16,	18	to	22,	and	24	to	28	followed	by	25	days	of	AS-700.
